35,700 Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Profund Advisors LLC

Profund Advisors LLC boosted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 297.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,715 shares of the company’s stock after buying an additional 35,700 shares during the quarter. Profund Advisors LLC’s holdings in Amphastar Pharmaceuticals were worth $1,232,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in AMPH. Dimensional Fund Advisors LP boosted its position in Amphastar Pharmaceuticals by 12.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock valued at $39,726,000 after buying an additional 228,262 shares during the period. Renaissance Technologies LLC increased its position in shares of Amphastar Pharmaceuticals by 1.7% during the first quarter. Renaissance Technologies LLC now owns 553,900 shares of the company’s stock worth $10,851,000 after acquiring an additional 9,200 shares during the period. Systematic Financial Management LP raised its stake in shares of Amphastar Pharmaceuticals by 4.0% during the first quarter. Systematic Financial Management LP now owns 452,898 shares of the company’s stock valued at $8,872,000 after acquiring an additional 17,318 shares in the last quarter. Denali Advisors LLC raised its stake in shares of Amphastar Pharmaceuticals by 41.1% during the second quarter. Denali Advisors LLC now owns 375,965 shares of the company’s stock valued at $7,587,000 after acquiring an additional 109,500 shares in the last quarter. Finally, Pacer Advisors Inc. raised its stake in shares of Amphastar Pharmaceuticals by 47.1% during the first quarter. Pacer Advisors Inc. now owns 261,483 shares of the company’s stock valued at $5,122,000 after acquiring an additional 83,739 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Down 2.5%

NASDAQ:AMPH opened at $27.03 on Tuesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.40 and a quick ratio of 1.71. Amphastar Pharmaceuticals, Inc. has a 1-year low of $16.65 and a 1-year high of $29.52. The company has a 50-day moving average of $24.87 and a 200 day moving average of $22.30. The firm has a market cap of $1.15 billion, a PE ratio of 10.53, a price-to-earnings-growth ratio of 5.14 and a beta of 0.90.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. The business had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. As a group, research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on AMPH shares. Weiss Ratings upgraded Amphastar Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 16th. Barclays raised their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 18th. Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Wells Fargo & Company lifted their target price on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Finally, Wall Street Zen cut Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday. Seven investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $22.50.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Richard Prins sold 7,973 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $20.30, for a total value of $161,851.90. Following the completion of the sale, the director owned 29,625 shares of the company’s stock, valued at approximately $601,387.50. This represents a 21.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William Peters sold 4,139 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $25.00, for a total transaction of $103,475.00. Following the transaction, the chief financial officer owned 168,707 shares in the company, valued at approximately $4,217,675. This represents a 2.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 33,479 shares of company stock valued at $763,922. Company insiders own 29.60% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.